Search Results

Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material.

Irvine-based Biogennix, LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, announced the launch of its new OsteoSPAN Fiber Matrix.

Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced today that the second quarter of 2022 was the best in company history.

Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced that its DirectCell Advanced Bone Grafting System has already been used in over 500 cases.

Irvine-based Biogennix announced today that 2021 was the best sales year in company history.

Irvine-based Biogennix, an advanced osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, is celebrating the 10th anniversary of its first clinical case.

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced the launch of its new Agilon® Strip bone grafting product.

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that 2019 has been its best sales year in company history

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, continues to operate and supply product to the medical community through the global coronavirus crisis and has been preparing for the anticipated surge in demand for surgical procedures when normal operations resume.